Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22562902 | 0.83 | NCF1 (0.46) | NCF1 | |
| SCHEMBL3574921 | 0.83 | HRH3 (0.36) | SLC18A3NCF1CHRM2CHRM1CHRM3 | |
| SCHEMBL22932478 | 0.80 | OPRL1 (0.39) | SLC18A3 | |
| SCHEMBL23788363 | 0.76 | USP1 (0.32) | — | |
| SCHEMBL1700960 | 0.76 | NCF1 (0.39) | NCF1 | |
| SCHEMBL1700965 | 0.76 | NCF1 (0.39) | NCF1 | |
| SCHEMBL24818350 | 0.75 | LTA4H (0.33) | — | |
| SCHEMBL12424517 | 0.75 | USP1 (0.33) | — | |
| SCHEMBL4704171 | 0.74 | NCF1 (0.52) | NCF1 | |
| SCHEMBL2157696 | 0.72 | MAP3K12 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116600810-A | Dihydrofuranopyridine derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116438182-A | 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase | 活力疗法公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | SLC18A3 4617/4885NCF1 506/4885CHRM2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.